ArticleDose-response : a publication of International Hormesis Society
Trastuzumab-Coated Nanoparticles Loaded With Docetaxel for Breast Cancer Therapy.
Article in Dose-response : a publication of International Hormesis Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 54 citations in OpenAlex.
- Clinical advances and challenges of antibody-mediated targeted drug delivery in breast cancer therapeutics.Discover oncology · 2026Review
- Development, Characterization, and Evaluation of Chi-Tn mAb-Functionalized DOTAP-PLGA Hybrid Nanoparticles Loaded with Docetaxel for Lung Cancer Therapy.Pharmaceutics · 2025Article
- Converging frontiers in cancer treatment: the role of nanomaterials, mesenchymal stem cells, and microbial agents-challenges and limitations.Discover oncology · 2024Review
- Effective Use ofCurrent issues in molecular biology · 2024Article
- Targeted Hybrid Nanocarriers as Co-Delivery Systems for Enhanced Cancer Therapy.Advanced pharmaceutical bulletin · 2024Review
- Poly(lactic-co-glycolic acid) nanoparticle fabrication, functionalization, and biological considerations for drug delivery.Biomicrofluidics · 2024Review
- Cancer immunotherapy and its facilitation by nanomedicine.Biomarker research · 2024Review
- Boosting antitumor efficacy using docetaxel-loaded nanoplatforms: from cancer therapy to regenerative medicine approaches.Journal of translational medicine · 2024Review
- Analytical Techniques for Characterizing Tumor-Targeted Antibody-Functionalized Nanoparticles.Life (Basel, Switzerland) · 2024Review
- Advancements in Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Breast Cancer Therapy.Current pharmaceutical design · 2024Review
- Nanoparticle-mediated cancer cell therapy: basic science to clinical applications.Cancer metastasis reviews · 2023Review
- Targeting prostate cancer with docetaxel-loaded peptide 563-conjugated PEtOx-co-PEIAmino acids · 2023Article
- Organic Nanodelivery Systems as a New Platform in the Management of Breast Cancer: A Comprehensive Review from Preclinical to Clinical Studies.Journal of clinical medicine · 2023Review
- Role of Nanotechnology in Overcoming the Multidrug Resistance in Cancer Therapy: A Review.Molecules (Basel, Switzerland) · 2022Review
- Anticancer Drugs: Recent Strategies to Improve Stability Profile, Pharmacokinetic and Pharmacodynamic Properties.Molecules (Basel, Switzerland) · 2022Review
- Naturally Equipped Urinary Exosomes Coated Poly (2-ethyl-2-oxazoline)-Poly (D, L-lactide) Nanocarriers for the Pre-Clinical Translation of Breast Cancer.Bioengineering (Basel, Switzerland) · 2022Article
- Review
- Recent Advances in the Surface Functionalization of PLGA-Based Nanomedicines.Nanomaterials (Basel, Switzerland) · 2022Review
- Recent advances in the development of biocompatible nanocarriers and their cancer cell targeting efficiency in photodynamic therapy.Frontiers in chemistry · 2022Review
- Current Progress in Cancer Treatment Using Nanomaterials.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Docetaxel (DTX) is commonly used for breast cancer treatment. Tween 80 used for DTX dissolution in its clinical formulation causes severe hypersensitivity and other adverse reactions. In this study, trastuzumab (Tmab)-coated lipid-polymer hybrid nanoparticles (PLNs) were prepared, composed of poly (d, l-lactide-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.